BACKGROUND: Chronic cough is a common clinical problem worldwide. Although many patients have underlying precipitating conditions such as asthma, gastroesophageal reflux, or rhinitis, many remain symptomatic despite treating these conditions. New approaches are needed for the treatment of this group of patients. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to determine whether 250 g of azithromycin three times a week for 8 weeks would affect the Leicester Cough Questionnaire (LCQ) score in 44 patients with treatment-resistant cough. Cough severity on a visual analog scale and bronchial exhaled nitric oxide were measured as secondary outcomes. RESULTS: There was a clinically important improvement in LCQ score with azithromycin (mean change, 2.4; 95% CI, 0.5 to 4.2) but not placebo (mean change, 0.7; 95% CI, -0.6 to 1.9), but the between-group difference was not statistically significant (P = .12). There were no significant between-group differences for any of the secondary outcome measures. Looking at subgroups of responders, there was a large and significant improvement in LCQ score in patients with chronic cough and a concurrent diagnosis of asthma who were treated with azithromycin (mean, 6.19; 95% CI, 4.06 to 8.32). CONCLUSIONS: Treatment with low-dose azithromycin for 8 weeks did not significantly improve LCQ score compared with placebo. The use of macrolides for treatment-resistant cough cannot be recommended from this study, but they may have a place in the treatment of chronic cough associated with asthma; this is worthy of further investigation. TRIAL REGISTRY: WHO International Clinical Trials Registry; No.: ISRCTN75749391. URL: http://apps.who.int.
BACKGROUND: Chronic cough is a common clinical problem worldwide. Although many patients have underlying precipitating conditions such as asthma, gastroesophageal reflux, or rhinitis, many remain symptomatic despite treating these conditions. New approaches are needed for the treatment of this group of patients. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to determine whether 250 g of azithromycin three times a week for 8 weeks would affect the Leicester Cough Questionnaire (LCQ) score in 44 patients with treatment-resistant cough. Cough severity on a visual analog scale and bronchial exhaled nitric oxide were measured as secondary outcomes. RESULTS: There was a clinically important improvement in LCQ score with azithromycin (mean change, 2.4; 95% CI, 0.5 to 4.2) but not placebo (mean change, 0.7; 95% CI, -0.6 to 1.9), but the between-group difference was not statistically significant (P = .12). There were no significant between-group differences for any of the secondary outcome measures. Looking at subgroups of responders, there was a large and significant improvement in LCQ score in patients with chronic cough and a concurrent diagnosis of asthma who were treated with azithromycin (mean, 6.19; 95% CI, 4.06 to 8.32). CONCLUSIONS: Treatment with low-dose azithromycin for 8 weeks did not significantly improve LCQ score compared with placebo. The use of macrolides for treatment-resistant cough cannot be recommended from this study, but they may have a place in the treatment of chronic cough associated with asthma; this is worthy of further investigation. TRIAL REGISTRY: WHO International Clinical Trials Registry; No.: ISRCTN75749391. URL: http://apps.who.int.
Authors: Guy G Brusselle; Christine Vanderstichele; Paul Jordens; René Deman; Hans Slabbynck; Veerle Ringoet; Geert Verleden; Ingel K Demedts; Katia Verhamme; Anja Delporte; Bénédicte Demeyere; Geert Claeys; Jerina Boelens; Elizaveta Padalko; Johny Verschakelen; Georges Van Maele; Ellen Deschepper; Guy F P Joos Journal: Thorax Date: 2013-01-03 Impact factor: 9.139
Authors: Paul M O'Byrne; Soren Pedersen; Lars-Göran Carlsson; Finn Radner; Anders Thorén; Stefan Peterson; Pierre Ernst; Samy Suissa Journal: Am J Respir Crit Care Med Date: 2010-10-01 Impact factor: 21.405
Authors: Alyn H Morice; Madhav S Menon; Siobhan A Mulrennan; Caroline F Everett; Caroline Wright; Jennifer Jackson; Rachel Thompson Journal: Am J Respir Crit Care Med Date: 2006-11-22 Impact factor: 21.405
Authors: Linjie Zhang; Sílvio O M Prietsch; Ana Paula Mendes; Andrea Von Groll; Gicelle Porto Rocha; Lillian Carrion; Pedro Eduardo Almeida Da Silva Journal: Respirology Date: 2013-02 Impact factor: 6.424
Authors: Markus Hilty; Conor Burke; Helder Pedro; Paul Cardenas; Andy Bush; Cara Bossley; Jane Davies; Aaron Ervine; Len Poulter; Lior Pachter; Miriam F Moffatt; William O C Cookson Journal: PLoS One Date: 2010-01-05 Impact factor: 3.240
Authors: Kian Fan Chung; Lorcan McGarvey; Woo-Jung Song; Anne B Chang; Kefang Lai; Brendan J Canning; Surinder S Birring; Jaclyn A Smith; Stuart B Mazzone Journal: Nat Rev Dis Primers Date: 2022-06-30 Impact factor: 65.038
Authors: Alyn H Morice; Eva Millqvist; Kristina Bieksiene; Surinder S Birring; Peter Dicpinigaitis; Christian Domingo Ribas; Michele Hilton Boon; Ahmad Kantar; Kefang Lai; Lorcan McGarvey; David Rigau; Imran Satia; Jacky Smith; Woo-Jung Song; Thomy Tonia; Jan W K van den Berg; Mirjam J G van Manen; Angela Zacharasiewicz Journal: Eur Respir J Date: 2020-01-02 Impact factor: 16.671
Authors: Malene Plejdrup Hansen; Anna M Scott; Amanda McCullough; Sarah Thorning; Jeffrey K Aronson; Elaine M Beller; Paul P Glasziou; Tammy C Hoffmann; Justin Clark; Chris B Del Mar Journal: Cochrane Database Syst Rev Date: 2019-01-18
Authors: Jonas Christian Schupp; Urs Alexander Fichtner; Björn Christian Frye; Katja Heyduck-Weides; Surinder S Birring; Wolfram Windisch; Carl-Peter Criée; Joachim Müller-Quernheim; Erik Farin Journal: PLoS One Date: 2018-10-04 Impact factor: 3.240